Friday , August 12 2022

Why rare types & # 39; cancer have a lower incidence and worse prognosis



[ad_1]

Visiting the-country, David Humphreys, of – – Health Policy Director & # 39; to – Unit & # 39; the – Intelligence & # 39; The Economist, Presented a report on the state of the approach to rare types & # 39; cancer in Latin America, including the situation in Argentina.

The investigation, called Types & # 39; rare cancer in Latin America: Challenges and present opportunities for advancement, Sought to generate more awareness challenges to improve health care and prognosis & # 39; patients & # 39; & # 39 any kind; rare cancer, Which are those incidence & # 39; less than six cases per 100 thousand inhabitants per year, focused on Argentina, Brazil, Colombia and Mexico.

Among the data collected, the main barriers to treatment and opportunities to improve the results obtained are detailed, to capture the attention of those involved in & # 39; this problem.

"Epidemiological data suggest that the incidence of & # 39; these cancers in Latin America is, b & # 39; In general, slower than f & # 39; countries with higher incomes. When analyzing rates & # 39; incidence and mortality is observed rare cancer have worse prognosis in Latin American countries than in & # 39; richest countries. The local survival rates are comparable to & # 39; those registered in India, China and Africa & # 39; South, "said Humphreys.

Based on – research conducted by The Economist In response to a request from Merck, by the Intelligence Unit, developed a series of & # 39; recommendations to optimize the approach to the following conditions:

Develop and implement plans or strategies at national level: Like EUROPLAN implemented by European countries, Latin America can & # 39; establish a regional project to ensure consistency in the treatment of & # 39; rare cancer. This helps to stimulate the development and implementation of & # 39; strategic plans.

Create comprehensive records at national and regional level: Records link the cancer data to the population essential to obtain epidemiological data, prevention plan & # 39; rare cancer and activities of & # 39; control. Developing & # 39; regional registry is the natural step to standardize the collection & # 39; data on rare cancers in Latin America.

Generate research collaboration at national, regional and international level: The oncology research is essential to increase the understanding of rare cancers and improve the management of the disease. It is recommended that the Latin American countries participate in & # 39; initiatives & # 39; national research, regional and international on rare cancers and b & # 39; thus contributing to the overall knowledge by benefiting from the exchange & # 39; ideas.

Improving treatment by & # 39; of & # 39 centers; excellence: centers is essential to develop & # 39; excellence and networks & # 39; experts or groups & # 39; work. The expert networks have the potential to improve outcomes and reduce inequality, since they promote greater awareness of rare cancer by providing support for the & # 39; treatment centers. The European models and & # 39; American & # 39; Above may be suitable for application in the region & # 39; Latin America.

David Humphreys stressed that "in Latin America, autoimmune diseases and access to health were, historically, issues & # 39; high priority for legislators and actors involved in the issue. However, because the life expectancy and health care, b & # 39; in general, have improved in the region, b & # 39; longer population there was an increased incidence of & # 39; chronic diseases. "Cancer is a focal point of & # 39; particular importance, b & # 39; more than one million new cases each year in Latin America and the Caribbean.

Although progress in early diagnosis and national plans & # 39; prevention, much remains to be done, such as the development of & # 39; Patient registry and combating disparities in access to treatment. F & # 39; & # 39 cases, a rare cancer, the challenge is even greater.

[ad_2]
Source link